Researchers
Paul Albert

Paul Albert

PhD

Senior Scientist, Neuroscience

Ottawa Hospital Research Institute

Professor, Medicine

University of Ottawa Brain and Mind Research Institute

Associate Program Director, Neuroscience

Ottawa Hospital Research Institute

Contact

palbert@ohri.ca

613-562-5800 8307

OHRI (Neuroscience) 451 Smyth Road Ottawa, ON K1H-8M5 Canada

ORCID 0000-0002-1809-3554

Research Groups

Research Group
Albert Lab
Our lab is uncovering some of the factors that lead to depression and determine whether patients will respond to antidepressants. Antidepressants l...

Bio

Dr. Albert obtained his B.Sc. in Physiology/Biochemistry from McGill University, Montreal (1980) and his Ph.D. in Pharmacology from Harvard University, Boston (1985) under Dr. Armen H. Tashjian, Jr. on Stimulus-secretion coupling in rat pituitary cells. He did post-doctoral studies with Drs. Herbert and Olivier Civelli on molecular cloning of serotonin and dopamine receptor genes. He became Assistant Professor, then tenured Associate Professor in the Dept. of Pharmacology and Therapeutics, McGill University (1989-95), and then moved to Ottawa as CIHR/Novartis Michael Smith Chair in Neuroscience, University of Ottawa. He is currently Full Professor of Medicine and Senior Scientist and the Associate Director of Neuroscience at OHRI.

News

Publications

Rapid reorganization of serotonin projections and antidepressant response to 5-HT1A-biased agonist NLX-101 in fluoxetine-resistant cF1ko mice

2024-12-01 Go to publication

CaMKIV-Mediated Phosphorylation Inactivates Freud-1/CC2D1A Repression for Calcium-Dependent 5-HT1A Receptor Gene Induction

2024-06-04 Go to publication

Chronic Desipramine Reverses Deficits in Cell Activity, Norepinephrine Innervation, and Anxiety–Depression Phenotypes in Fluoxetine-Resistant cF1ko Mice

2024-01-17 Go to publication

Transcriptional Regulation of the Human 5-HT1A Receptor Gene by Lithium: Role of Deaf1 and GSK3β

2023-10-26 Go to publication

Mood disturbances in Parkinson's disease: From prodromal origins to application of animal models

2023-06-01 Go to publication
View More on ORCiD

2025-2027, Targeting serotonin to improve depression and dementia in heart and Alzheimer disease. Brain Heart Interconnectome.

2025-2026, Early raphe nucleus pathology and depression with a-syn seeding: A novel approach to targeting mTOR for prodromal Parkinsonism. (PI: Shawn Hayley) Parkinson Research Consortium.

2025-2029, Enhancing neuroplasticity for behavioral and cognitive recovery after stroke. Heart and Stroke Foundation, Canada.

2021-2026, Astroglial cells as mediators of sex and hormone- dependent differences in depressive like behaviours. (PI: Natalina Salmaso) Canadian Institutes of Health Research

2022-2025, Enhancing neuroplasticity for behavioral recovery post-stroke. Heart & Stroke Foundation Canada

2020-2025, Overcoming resistance to antidepressant treatment. Canadian Institutes of Health Research

Related Research at The Ottawa Hospital